Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection

Journal of Virology

Volumn 73, Issue 6, 1999, Pages 5225-5230

  Zhang, Peng Fei ^a   Chen, Xi ^a   Fu, Da Wei ^a,c   Margolick, Joseph B ^b   Quinnan Jr , Gerald V ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c National Vaccine and Serum Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNIZATION; MALE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

EID: 0006979165     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.6.5225-5230.1999     Document Type: Article

References (30)

1. Arendrup, M., A. Sonnerborg, B. Svennerholm, L. Akerblom, C. Nielsen, H. Clausen, S. Olofsson, J. O. Nielsen, and J. E. Hansen. 1993. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J. Gen. Virol. 74:855-863.
2. Back, N. K. T., L. Smit, M. Schutten, P. L. Nara, M. Tersmette, and J. Goudsmit. 1993. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J. Virol. 67:6897-6902.
3. Bergeron, L., N. Sullivan, and J. Sodroski. 1992. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus. J. Virol. 66:2389-2397.
4. Chen, Z., P. Zhou, D. D. Ho, N. R. Landau, and P. A. Marx 1997. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 71:2705-2714.
5. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. L. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV. Nature 381:661-666.
6. Haigwood, N. L., J. R. Shuster, G. K. Moore, H. Lee, P. V. Skiles, K. W. Higgins, P. J. Barr, C. George-Nascimento, and K. S. Steimer. 1990. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. AIDS Res. Hum. Retroviruses 6:855-869.
7. Higgins, D. G., and P. M. Sharp. 1989. Fast and sensitive multiple sequence alignments on a microcomputer. CABIOS 5:151-153.
8. Ho, D. D., M. S. C. Fung, Y. Cao, X. L. Li, C. Sun, and T. W. Chang. 1991. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc. Natl. Acad. Sci. USA 88:8949-8952.
9. Kaslow, R. A., D. G. Ostrow, R. Detels, J. P. Phair, B. F. Polk, and C. R. Rinaldo, Jr. 1987. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am. J. Epidemiol. 126:310-318.
10. Korber, B., S. Wolinsky, B. Haynes, K. Kunstman, R. Levy, M. Furtado, P. Otto, and G. Myers. 1992. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res. Hum. Retroviruses 8:1461-1465.
11. Langedijk, J. P., G. Zwart, J. Goudsmit, and R. H. Meloen. 1995. Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. AIDS Res. Hum. Retroviruses 11:1153-1162.
12. Liou, H. C., W. C. Sha, M. L. Scott, and D. Baltimore. 1994. Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol. Cell. Biol. 14:5349-5359.
13. Mascola, J., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke. 1994. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169:48-54.
14. McKeating, J. A., J. Giw, J. Goudsmit, L. H. Pearl, C. Mulder, and R. A. Weiss. 1989. Characterization of HIV-1 neutralization escape mutants. AIDS 3:777-784.
15. McKnight, A., and P. R. Clapham. 1995. Immune escape and tropism of HIV. Trends Microbiol. 3:356-361.
16. McKnight, A., P. R. Clapham, J. Goudsmit, R. Cheingsong-Popov, J. N. Weber, and R. A. Weiss. 1992. Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 6:799-802.
17. Nara, P. L., L. Smit, N. Dunlop, W. Hatch, M. Merges, D. Waters, J. Kelliher, R. C. Gallo, P. J. Fischinger, and J. Goudsmit. 1990. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J. Virol. 64:3779-3791.
18. O'Brien, W. A., I. S. Y. Chen, D. D. Ho, and E. S. Daar. 1992. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J. Virol. 66:3125-3130.
19. Overbaugh, J., and L. M. Rudensey. 1992. Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. J. Virol. 66:5937-5948.
20. Park, E. J., L. K. Vujcic, R. Anand, T. S. Theodore, and G. V. Quinnan. 1998. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant HIV-1 MN to antibodies directed at V3 and non-V3 epitopes. J. Virol. 72:7099-7107.
21. Quinnan, G. V., P. F. Zhang, D. W. Fu, M. Dong, and J. Margolick. 1998. Episodic evolution of neutralizing antibody response in patients with HIV-1 infection. AIDS Res. Hum. Retroviruses 14:939-949.
22. Reitz, M. S., C. Wilson, C. Naugle, R. C. Gallo, and M. Robert-Guroff. 1988. Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 54:57-63.
23. Robert-Guroff, M., M. S. Reitz, W. G. Robey, and R. C. Gallo. 1986. In vitro generation of an HTLV-III variant by neutralizing antibody. J. Immunol. 137:3306-3309.
24. Sawyer, L. A., D. A. Katzenstein, R. M. Hendry, E. J. Boone, L. K. Vujcic, C. C. Williams, S. L. Zeger, A. J. Saah, C. R. Rinaldo, Jr., J. P. Phair, J. V. Giorgi, and G. V. Quinnan, Jr. 1990. Possible beneficial effects of neutralizing antibodies and antibody-dependent cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6: 341-356.
25. Stuve, L. L., S. Brown-Shimer, C. Pachl, R. Naharian, D. Diaz, and R. L. Burke. 1987. Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J. Virol. 61:326-335.
26. Vujcic, L. K., and G. V. Quinnan, Jr. 1995. Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res. Hum. Retroviruses 11:783-787.
27. Vujcic, L. K., D. H. Shepp, M. Klutch, M. A. Wells, R. M. Hendry, A. E. Wittek, L. Krilov, and G. V. Quinnan. 1988. Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J. Infect. Dis. 157:1047-1050.
28. Wahlberg, J., J. Albert, J. Lundeberg, A. Von Gegerfelt, K. Broliden, G. Utter, E. M. Fenyo, and M. Uhlen. 1991. Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. AIDS Res. Hum. Retroviruses 7:983-990.
29. Watkins, B. A., S. Buge, K. Aldrich, A. E. Davis, J. Robinson, M. S. Reite, Jr., and M. Robert-Guroff. 1996. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J. Virol. 70:8431-8437.
30. Watson, J. C., S. C. Hadler, C. A. Dykewicz, S. Reef, and L. Phillips. 1998. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 47(RR-8):1-57.